Athena Athena

X
[{"orgOrder":0,"company":"Two Cells","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai and TWOCELLS Announce the Decision of the Termination of License Agreement on Investigational Regenerative Cellular Medicine for Knee Chondrogenesis (gMSC\u00ae1)","therapeuticArea":"Orthopedics\/Orthopedic Surgery","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III"}]

Find Clinical Drug Pipeline Developments & Deals by Two Cells

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Upon termination of the Agreement, all domestic and foreign rights with respect to guaranteed Mesenchymal Stem Cell 1 (gMSC®1), a regenerative cellular medicine for chondrogenesis in the knee, granted to Chugai from TWOCELLS will be returned to TWOCELLS.

            Lead Product(s): gMSC1

            Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: gMSC1

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Chugai Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination April 13, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY